

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (kl-81)

ZILEBESIRAN SODIUM

PRONUNCIATION

zil" bee sir' an



THERAPEUTIC CLAIM

Treatment of hypertension

CHEMICAL NAMES

1. RNA, (Gm-sp-Um-sp-Cm-Am-Um-Cm-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)A-(2'-deoxy-2'-fluoro)A-Um-Gm-Am-Gm-Am-Gm-Um-Am-Cm-Am), 3'-[[[2S,4R)-1-[29-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-1,12,19,25-tetraoxo-16-oxa-13,20,24-triazanonacos-1-yl]-4-hydroxy-2-pyrrolidinyl]methyl hydrogen phosphate] sodium salt, complex with RNA (Um-sp-(2'-deoxy-2'-fluoro)G-sp-Um-Am-Cm-(3'→3')-[1-de-β-D-ribofuranosyl-1-[(2S)-2,3-dihydroxypropyl]]m<sup>5</sup>U-(2'→5')-Cm-Um-Cm-Am-Um-Um-Gm-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)G-Am-Um-Gm-Am-Cm-sp-Gm-sp-Am) sodium salt (1:21:1:22) (CAS Name)
2. [(2S,4R)-1-{1-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy}methyl)-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl)-4-hydroxypyrrolidin-2-yl]methyl all-*P*-ambo-2'-*O*-methyl-*P*-thioguanlyl-(3'→5')-2'-*O*-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methyl-3'-adenylate, duplex with all-*P*-ambo-2'-*O*-methyl-*P*-thioadenylyl-(5'→3')-2'-*O*-methyl-*P*-thioguanlyl-(5'→3')-2'-*O*-methylcytidylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-*O*-methylguanylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-deoxy-2'-fluoroguanlylyl-(5'→3')-2'-*O*-methylguanylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-methylguanylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-*O*-methylcytidylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-*O*-methylcytidylyl-(5'→2')-1-de-β-D-ribofuranosyl-1-[(2S)-2,3-dihydroxypropyl]-5-methyluridylyl-(3'→3')-2'-*O*-methylcytidylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-*O*-methyl-*P*-thiouridylyl-(5'→3')-2'-deoxy-2'-fluoro-*P*-thioguanlylyl-(5'→3')-2'-*O*-methyluridine, sodium salt (1 :21 : 1 :22) (IUPAC Name)

# STRUCTURAL FORMULA



MOLECULAR FORMULA

C<sub>532</sub>H<sub>678</sub>F<sub>7</sub>N<sub>177</sub>Na<sub>43</sub>O<sub>321</sub>P<sub>43</sub>S<sub>6</sub>

MOLECULAR WEIGHT

17.33 kDa

TRADEMARKS

None yet

SPONSOR

Alnylam Pharmaceuticals, Inc.

DESIGNATION CODES

ALN-AGT01 sodium

CAS REGISTRY NUMBER

2380166-34-5

UNII

A8P3J9MPQ3

bww

April 27, 2022

M21/84